ArticleCurrent drug delivery2026
Double Particle Surface Modification to Improve Key Properties of
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe ethanol extract of Pueraria lobatae Radix (EPL), a kind of medicinal herb powder with unacceptable behaviour (poor compactibility and slow dissolution rate), has the potential to be improved by double particle surface design by fluid-bed coating. This involves surface coating with plastic Hydroxypropyl Methylcellulose (HPMC) and surface pore formation induced by NH
methodsThe EPL drug was selected as the model for investigation. The formulation of the Composite Particles (CPs) was optimized using a central composite design. Subsequently, the pivotal tabletrelated attributes were contrasted between the optimized porous HPMC-coated EPL CPs and the pure HPMC-coated EPL CPs. Finally, the stability and applicability of the porous HPMC-coated EPL CPs were studied.
resultsThe results demonstrated that (i) the optimized use levels of HPMC and NH4HCO3 for the porous CPs were 8.42% and 15.00% (w/w), respectively; (ii) the compactibility and tablet dissolution rate of the porous HPMC-coated EPL CPs were significantly enhanced in comparison to those produced from the pure HPMC-coated CPs; and (iii) the porous HPMC-coated CPs exhibited good stability and universal applicability in direct compaction.
conclusionAs a whole, the combination of polymeric coating and porous design proved effective in enhancing the compactibility and dissolution rate of EPL-based CPs while also rendering them suitable for direct compaction. These findings are conducive to the expansion of the application of fluidbed coating technology and the simultaneous improvement of the quality and efficacy of some drug tablets.
Indexed as
Identifiers
41268827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.